Mereo Biopharma Group PLC banner

Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 0.3388 USD 2.98% Market Closed
Market Cap: $53.9m

Intrinsic Value

MREO latest financial reports are more than 2 years old.

The intrinsic value for Mereo Biopharma Group PLC (MREO) under the Base Case is 0.2097 USD. Compared with the current market price of 0.3388 USD, the stock appears Overvalued by 38%.

MREO Intrinsic Value
0.2097 USD
Overvaluation 38%
Intrinsic Value
Price $0.3388
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value $0.17
Get notified when the price drops into your buy zone
Current Price $0.34
Intrinsic Value $0.21
Margin of Safety 20% $0.17
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about MREO?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is MREO valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Mereo Biopharma Group PLC.

Explain Valuation
Alternatives to MREO

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Mereo Biopharma Group PLC

Wall St
Price Targets

Capital Returns

Competitive Landscape

Ownership

MREO Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one MREO stock?

The intrinsic value for Mereo Biopharma Group PLC (MREO) under the Base Case is 0.2097 USD.

Is MREO stock undervalued or overvalued?

Compared with the current market price of 0.3388 USD, the stock appears Overvalued by 38%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett